473eP Ethnicity-based comparative analysis of overall survival in 30,000 HR+/HER2− metastatic breast cancer patients treated with CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib): A real-world meta-analysis

Conclusions: Nearly half of patients with HR+/HER2-MBC had sarcopenia at the time of metastatic diagnosis, with a clinically relevant 12 months reduction in OS.Our findings underscore the need for increased awareness of sarcopenia in routine oncological care.Whether early identification of sarcopenia combined with nutritional counseling and physical activity interventions can improve patient outcomes remains to be determined.